Liu Huanhuan, Xu Minmin, He Qiongzi, Wei Peng, Ke Mengying, Liu Shijia
Department of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
College of Pharmacy, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China.
Front Med (Lausanne). 2022 Sep 8;9:814839. doi: 10.3389/fmed.2022.814839. eCollection 2022.
Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) characterized by skip intestinal lesions that can occur in any part of the gastrointestinal tract. Currently, the diagnosis of CD is based on clinical history, physical examination and complementary diagnostic tests. It is challenging for physicians to make a definitive diagnosis. This study aimed to analyze the variation in metabolites in CD serum and identify potential predictive biomarkers of CD diagnosis. We collected serum samples from 316 subjects, including patients with CD and healthy controls (HCs). Serum metabolomics was conducted using liquid chromatography coupled to mass spectrometry. Potential biomarkers were screened and evaluated by univariate and multivariate analyses. A panel of two metabolites (deoxycholic acid and palmitic amide) was identified as a specific biomarker of CD. Receiver operating characteristic analysis (ROC) showed that the panel had a sensitivity of 80.25% with a specificity of 95.54% in discriminating CD patients from healthy controls. The biomarkers identified are increased in CD compared with healthy controls. Our approach successfully identified serum biomarkers associated with CD patients. The potential biomarkers indicated that CD metabolic disturbance might be associated with bile acid biosynthesis, fatty acids and energy metabolism.
克罗恩病（CD）是炎症性肠病（IBD）的一种亚型，其特征为跳跃性肠道病变，可发生于胃肠道的任何部位。目前，CD的诊断基于临床病史、体格检查及辅助诊断测试。医生做出明确诊断具有挑战性。本研究旨在分析CD血清中代谢物的变化，并确定CD诊断的潜在预测生物标志物。我们收集了316名受试者的血清样本，包括CD患者和健康对照（HC）。采用液相色谱-质谱联用技术进行血清代谢组学分析。通过单变量和多变量分析筛选和评估潜在生物标志物。一组两种代谢物（脱氧胆酸和棕榈酰胺）被确定为CD的特异性生物标志物。受试者工作特征分析（ROC）表明，该组合在区分CD患者和健康对照时，敏感性为80.25%，特异性为95.54%。与健康对照相比，CD中鉴定出的生物标志物增加。我们的方法成功鉴定出与CD患者相关的血清生物标志物。潜在生物标志物表明，CD代谢紊乱可能与胆汁酸生物合成、脂肪酸和能量代谢有关。
